Brief: Oncozenge Updates On Taking BupiZenge To Market

Oncozenge AB

24/11/2023 13:52

Nov 24 (Reuters) - Oncozenge AB  ONCOZ.ST :
    * PROVIDES STRATEGY UPDATE
    * ESTIMATED ANNUAL MARKET POTENTIAL OF $200M TO $1.3B IN EUROPE AND USA, WITH ADDITIONAL
UPSIDE IN
REST OF WORLD
    * SEES A NEED FOR ADDITIONAL OPERATIONAL CAPITAL IN 2025 SHOULD ONGOING PARTNERING EFFORTS
BE
DELAYED
    * TO PROVIDE DETAILS OF FINANCIAL OUTLOOK IN YEAR-END REPORT FOR 2023
    * 2024 WILL BE FOCUSED ON BUSINESS DEVELOPMENT AND VALUE ADDING ACTIVITIES SUCH AS SECURING
NEW IP
AND PARTNERSHIPS
    * SHORTEST PATH TO APPROVAL IN A MARKET WITH SIGNIFICANT COMMERCIAL POTENTIAL IS IN EU,
    * PREVIOUSLY COMMUNICATED CAPITAL NEEDS AMOUNTING TO SEK 60 MILLION WILL NOT BE REQUIRED
    * STARTED PREPARATIONS TO FILE FOR PRIORITY MEDICINES (PRIME) STATUS WITH EMA, WHICH
PROVIDES
ENHANCED REGULATORY SUPPORT TO DRUG CANDIDATES
    * EU BUPIZENG MARKET APPROVAL IN 2026 IS CONSIDERED FEASIBLE

Source text for Eikon:  ID:nWkr3FYKJp 
Further company coverage:  ONCOZ.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))